3 completed, 1 active not recruiting, 1 recruiting. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
Follow bosutinib: new trials by email Literature Review of bosutinib trials Research Report on bosutinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Olverembatinib (HQP1351) in Patients With CML-CP olverembatinib, Bosutinib - Chronic Myeloid Leukemia, CML | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 333 | 2024-02-05 | 2026-09-15 |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Imatinib, Nilotinib, Bosutinib - Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 405 | 2021-10-06 | 2026-08-28 |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs Asciminib, Bosutinib - Chronic Myelogenous Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 233 | 2017-10-26 | 2026-08-18 |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Bosutinib, Imatinib - Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive | Phase 3 | Completed | Pfizer | 536 | 2014-07-15 | 2021-05-18 |
| Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML Bosutinib, imatinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Pfizer | 502 | 2008-02-05 | 2019-01-08 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Philadelphia Chromosome (2) · Bone Marrow Diseases (1) · Bronchiolitis Obliterans Syndrome (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Myeloid (1) · Leukemia, Myeloid, Chronic-Phase (1) · Neoplasms by Histologic Type (1) · Pathologic Processes (1) · Translocation, Genetic (1)
Novartis Pharmaceuticals (2) · Pfizer (2) · Ascentage Pharma Group Inc. (1)
Canada (5) · France (5) · Germany (5) · Italy (5) · South Korea (5) · Spain (5) · United Kingdom (5) · United States (5) · Australia (4) · Belgium (4) · Hungary (4) · Japan (4) · Singapore (4) · Czechia (3) · India (3)
PMID 35235189, PMID 37553873, PMID 22825216, PMID 22949154, PMID 23116602, PMID 24919837, PMID 24944159, PMID 29091516, PMID 33851349, PMID 34407542, PMID 35643868, PMID 35764773, PMID 36168187, PMID 36524980, PMID 37431294, PMID 38820078, PMID 40334072, PMID 41397287, PMID 42339511
2016 (1), 2023 (1)